This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Elotuzumab parenteral

Updated 2 Feb 2023 | Elotuzumab


Infusions of elotuzumab.

Drugs List

  • elotuzumab 300mg powder for concentrate for soln for infusion vial
  • elotuzumab 400mg powder for concentrate for soln for infusion vial
  • EMPLICITI 300mg powder for concentrate for soln for infusion vial
  • EMPLICITI 400mg powder for concentrate for soln for infusion vial
  • Therapeutic Indications


    Myeloma - multiple

    Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.

    Treatment of relapsed and refractory multiple myeloma in combination with pomalidomide and dexamethasone in adult patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.


    Due to the complexity and specialist nature of dosage regimens for the treatment of malignant disease, specific dosing information on this agent is not included.
    Doses may vary significantly if this agent is used as monotherapy or different combinations.
    When using this agent, specialist literature, national guidelines, cancer network protocols and Trust chemotherapy protocols should be consulted.


    For intravenous infusion only.


    Children under 18 years

    Precautions and Warnings

    Females of childbearing potential
    Serum bilirubin above 1.5 times upper limit of normal

    Advise ability to drive/operate machinery may be affected by side effects
    Combination therapy: refer to information for concomitant agent
    Pre-medicate with corticosteroids, antihistamines and H2 antagonists
    Premedication with antipyretic recommended
    Treatment to be initiated and supervised by a specialist
    Consult local policy on the safe use of anti-cancer drugs
    Must be given as an intravenous infusion
    Record name and batch number of administered product
    Staff: Not to be handled by pregnant staff
    Monitor closely any patient who develops new infection while on treatment
    Monitor patient throughout infusion and for at least 2 hours afterwards
    Monitor patients for development of second primary malignancies
    Advise patient to report symptoms of infection immediately
    Interrupt therapy/reduce infusion rate if infusion-related reactions occur
    May affect results of some laboratory tests
    Discontinue if grade 3 or higher infusion reaction occurs
    Female: Contraception required during and for 120 days after treatment
    Male: Contraception required during and for 6 months after treatment

    Pregnancy and Lactation


    Elotuzumab is contraindicated during pregnancy.

    The manufacturer recommends that elotuzumab should not be used during pregnancy unless the clinical condition of the woman requires it. Elotuzumab is given in combination with lenalidomide or pomalidomide, which are contraindicated during pregnancy. Refer to lenalidomide and pomalidomide product information for details of the pregnancy prevention programme.


    Elotuzumab is contraindicated during breastfeeding.

    The manufacturer recommends that breastfeeding should be stopped during treatment with elotuzumab due to the combination treatment with lenalidomide or pomalidomide. Elotuzumab is not expected to be excreted in human milk however as it is given in combination with lenalidomide or pomalidomide, breastfeeding should be discontinued during treatment.

    Side Effects

    Anaphylactic reaction
    Chest pain
    Deep vein thrombosis (DVT)
    Herpes zoster
    Hypersensitivity reactions
    Infusion related reaction
    Mood changes
    Night sweats
    Oropharyngeal pain
    Upper respiratory tract infection
    Weight loss


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Empliciti 300mg and 400mg powder for concentrate for solution for infusion. Bristol-Myers Squibb Pharmaceutical Ltd. Revised January 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.